AstraZeneca Liver Cancer Treatment Accepted for Priority Review in U.S.
25 April 2022 - 9:03AM
Dow Jones News
By Michael Susin
AstraZeneca PLC said Monday that its liver cancer treatment
tremelimumab was accepted for priority review by U.S. federal
health regulators.
The Anglo-Swedish pharmaceutical giant said the action date for
the U.S. Food and Drug Administration's regulatory decision is
expected in the fourth quarter of 2022.
The company said a Phase 3 study includes a dose of tremelimumab
added to the immunotherapy Imfinzi, aiming to improve overall
survival of patients with unresectable liver cancer.
"The Himalaya Phase III trial showed an unprecedented three-year
overall survival in this setting with a single priming dose of
tremelimumab added to Imfinzi, highlighting the potential for this
regimen to improve longer-term survival outcomes," Susan Galbraith,
AstraZeneca's executive vice president, oncology research and
development, said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
April 25, 2022 02:48 ET (06:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
